Tower Research Capital LLC TRC Has $1.77 Million Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Tower Research Capital LLC TRC boosted its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 58.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 14,522 shares of the biotechnology company's stock after purchasing an additional 5,371 shares during the period. Tower Research Capital LLC TRC's holdings in Sarepta Therapeutics were worth $1,766,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the stock. Manchester Capital Management LLC increased its position in Sarepta Therapeutics by 86.6% during the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock worth $29,000 after buying an additional 110 shares during the last quarter. MassMutual Private Wealth & Trust FSB raised its stake in Sarepta Therapeutics by 169.6% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 156 shares during the period. Newbridge Financial Services Group Inc. bought a new stake in Sarepta Therapeutics in the 4th quarter valued at $36,000. Steward Partners Investment Advisory LLC lifted its holdings in Sarepta Therapeutics by 164.4% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company's stock valued at $38,000 after purchasing an additional 194 shares during the last quarter. Finally, Smartleaf Asset Management LLC boosted its position in Sarepta Therapeutics by 95.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 442 shares of the biotechnology company's stock worth $54,000 after purchasing an additional 216 shares during the period. 86.68% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on SRPT shares. Morgan Stanley cut their target price on shares of Sarepta Therapeutics from $196.00 to $182.00 and set an "overweight" rating for the company in a research note on Friday, April 11th. HC Wainwright restated a "neutral" rating and set a $75.00 price objective on shares of Sarepta Therapeutics in a research report on Wednesday, April 16th. Wells Fargo & Company started coverage on Sarepta Therapeutics in a research report on Friday, April 11th. They issued an "overweight" rating and a $115.00 target price on the stock. Deutsche Bank Aktiengesellschaft dropped their price target on Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating for the company in a report on Wednesday, March 19th. Finally, Royal Bank of Canada lowered Sarepta Therapeutics from an "outperform" rating to a "sector perform" rating and decreased their price objective for the company from $161.00 to $87.00 in a report on Monday, March 31st. Six equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $158.70.

Sarepta Therapeutics Price Performance

Sarepta Therapeutics stock traded up $0.30 during midday trading on Monday, reaching $60.74. The company's stock had a trading volume of 256,076 shares, compared to its average volume of 1,420,573. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The stock has a market cap of $5.89 billion, a PE ratio of 48.59 and a beta of 0.93. Sarepta Therapeutics, Inc. has a 52 week low of $48.01 and a 52 week high of $173.25. The business has a 50-day moving average price of $77.32 and a 200-day moving average price of $105.59.

Insider Activity

In other news, Director Claude Nicaise sold 2,491 shares of the stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the transaction, the director now directly owns 27,812 shares in the company, valued at approximately $2,771,187.68. This represents a 8.22 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 7.70% of the stock is currently owned by corporate insiders.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.